Rhapsody Venture Partners
Rhapsody Venture Partners is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Rhapsody Venture Partners.
Rhapsody Venture Partners is a company.
Key people at Rhapsody Venture Partners.
Rhapsody Venture Partners is a venture capital firm headquartered in Cambridge, Massachusetts, specializing in early-stage investments in hard tech and industrial science startups.[1][2][3][5] Their mission centers on co-creating and nurturing innovations in hard sciences, including materials science, engineering, chemistry, food technology, energy, life sciences, agriculture, and consumer products, by leveraging a network of scientists and experts to accelerate transformative solutions for sustainability and industrial challenges.[1][3][4] The firm's investment philosophy emphasizes data-driven partnerships, operational support, and active involvement in portfolio companies, drawing from managers' experience in over 50 tech and healthcare deals across North America and Europe, with notable biotech exits.[1] Rhapsody significantly impacts the startup ecosystem by leading seed and pre-seed rounds in university spinouts (e.g., Harvard, MIT, Caltech, Wyss Institute), bridging academic breakthroughs to commercial scale and fostering hard tech entrepreneurship amid rising demand for sustainable technologies.[4][5]
Rhapsody Venture Partners traces its roots to 2012, when it was founded in Cambridge, Massachusetts, initially focusing on investing in and operating industrial science startups.[2] Some sources note activity ramping up around 2016, aligning with the launch of dedicated funds.[5] Key figures include Managing Partner Carsten Boers, General Partner Bernard Lupien, and Principals Corrie Kavanaugh and Isabel Klein, who bring expertise in technology, healthcare, and strategic investments.[1][5] The firm's evolution has centered on hard tech, shifting from broad industrial science to specialized early-stage hard innovations like advanced materials and biomanufacturing, evidenced by funds closed in 2018, 2020, and a 2022 vintage still in market.[5] This progression reflects a deepening commitment to hands-on co-creation, exemplified by early bets like co-leading Chinova's 2018 pre-seed with DSM.[4]
Rhapsody rides the hard tech resurgence, capitalizing on trends like sustainable materials, advanced energy storage, and bio-based manufacturing amid climate imperatives and supply chain reshoring.[1][4] Timing is ideal post-2020, as industrial science startups address post-pandemic needs for resilient, green tech—e.g., mushroom-based preservatives (Chinova) reducing artificial ingredients, or solid-state batteries (Adden) enabling faster EV adoption.[4] Market forces like U.S. policy support for domestic innovation (e.g., CHIPS Act influences) and VC shift toward deep tech favor their model, with university spinouts providing a pipeline of defensible IP.[2][4] They influence the ecosystem by de-risking hard tech commercialization, proving mass-market viability (e.g., NODAR's 3D perception for affordable autonomy), and inspiring follow-on capital from players like SOSV and AgFunder.[4]
Rhapsody is poised to expand its portfolio in high-growth hard tech niches like advanced batteries and bioengineered foods, potentially closing larger funds to fuel follow-ons amid maturing exits.[4][5] Trends such as AI-accelerated materials discovery and global sustainability mandates will amplify their edge, especially with U.S.-centric focus amid geopolitical shifts.[3] Their influence may evolve toward larger syndicates and operator-led scaling, solidifying Cambridge as a hard tech hub—echoing their core strength in turning lab breakthroughs into ecosystem-defining companies.[1][2]
Key people at Rhapsody Venture Partners.
